Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Other Manufacturing

Health

Hospitals

Manufacturing

Omlyclo 300 mg

More Like This

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)